Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Renal Impairment Compared With Adult Participants With Normal Renal Function

NCT05940402 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05940402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05940402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Trial to Evaluate the Pharmacokinetics and Safety Following a Single Dose of Emraclidine in Adult Participants With Mild, Moderate, and Severe Renal Impairment Compared With Adult Participants With Normal Renal Function
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
July 24, 2023
Completion date
December 19, 2024
Enrollment
58 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment